Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8031337 | 0.89 | — | — | |
| SCHEMBL6130087 | 0.87 | — | — | |
| SCHEMBL8028145 | 0.87 | AGTR1 (0.39) | AGTR1 | |
| SCHEMBL8028142 | 0.87 | — | — | |
| SCHEMBL8018483 | 0.86 | — | — | |
| SCHEMBL8027695 | 0.86 | PPARG (0.39) | — | |
| SCHEMBL8031305 | 0.86 | AGTR1 (0.39) | AGTR1 | |
| Milfasartan SCHEMBL489256 | 0.85 | — | — | |
| SCHEMBL8018475 | 0.85 | PPARG (0.39) | — | |
| Potassium SCHEMBL8028319 | 0.85 | PPARG (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6096754-A | N-3 substituted pyrimidin-4-ones with AII antagonistic activity | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2000-08-01 | — | — | US | claimed |
| US-6096754-A | N-3 substituted pyrimidin-4-ones with AII antagonistic activity | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2000-08-01 | — | — | US | disclosed |
| EP-0900215-A1 | N-3 SUBSTITUTED PYRIMIDIN-4-ONES WITH AII ANTAGONISTIC ACTIVITY | ISTITUTO LUSO FARMACO D'ITALIA SpA (IT) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997040040-A1 | N-3 SUBSTITUTED PYRIMIDIN-4-ONES WITH AII ANTAGONISTIC ACTIVITY | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 1997-10-30 | — | — | WO | disclosed |